Skip to content
1887

Journal of General Virology header logo Journal of General Virology

Volume 74, Issue 3

Replication-defective recombinant adenovirus expressing the Epstein—Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin No Access

Abstract

A replication-defective recombinant adenovirus (Ad) expressing the full length Epstein—Barr virus (EBV) major envelope glycoprotein gp340/220 was tested for its ability to protect against EBV-induced lymphoma in the cottontop tamarin. Antibody responses against Ad capsid proteins and EBV gp340/220 were observed but these antibodies did not neutralize EBV . However, all immunized animals were protected against challenge following three intramuscular doses of the recombinant Ad. These data indicate that the recombinant Ad is potentially a useful vector for vaccination.

  • Received:
  • Accepted:
  • Published Online:
© Society for General Microbiology 1993
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-74-3-501
1993-03-01
2025-11-15

Metrics

Loading full text...

Full text loading...

References

  1. Alkhatib G., Briedis D. J. 1988; High-level eucaryotic in vitro expression of biologically active measles virus hemagglutinin by using an adenovirus type 5 helper-free vector system. Journal of Virology 62:2718–2727
     [Google Scholar]
  2. Attia M. A., Weiss D. W. 1966; Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumour resistance and enhancement in strain A mice infected with mammary tumour virus. Cancer Research 26:1787–1800
     [Google Scholar]
  3. Ballay A., Levrero M., Buendia M.-A., Tiollais P., Perricaudet M. 1985; In vitro and in vivo synthesis of the hepatitis B surface antigen and of the receptor for polymerised human serum albumin from recombinant human adenovirus. EM BO Journal 4:3861–3865
     [Google Scholar]
  4. Bejarano M. T., Masucci M. G., Morgan A. J., Morein B., Klein G., Klein E. 1990; Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation. Journal of Virology 64:1398–1401
     [Google Scholar]
  5. Berkner K. L. 1992; Expression of heterologous sequences in adenoviral vectors. Current Topics in Microbiology and Immunology 159:39–66
     [Google Scholar]
  6. Chroboczek J., Bieber F., Jacrot B. 1992; The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. Virology 186:280–285
     [Google Scholar]
  7. Cleary M. L., Epstein M. A., Finerty S., Dorpman R. F., Bornkamm G. W., Kirkwood J. K., Morgan A. J., Sklar J. 1985; Individual tumors of multifocal EBV induced malignant lymphomas in tamarins arise from different B-cell clones. Science 228:722–724
     [Google Scholar]
  8. Cooney E. L., Collier A. C., Greenberg P. D., Coombs R. W., Zarling J., Arditti D. E., Hoffman M. C., Hu S.-L., Corey L. 1991; Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337:567–572
     [Google Scholar]
  9. David E. M., Morgan A. J. 1988; Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography. Journal of Immunological Methods 108:231–236
     [Google Scholar]
  10. De Schryver A., Klein G., Hewetson J., Rochi G., Henlé W., Henlé G., Moss D., Pope J. H. 1974; Comparison of EBV neutralization tests based on abortive infection of transformation of lymphoid cells and their relation to membrane reactive antibodies (anti MA). International Journal of Cancer 13:353–362
     [Google Scholar]
  11. Eloit M., Gilardi-Hebenstreit P., Toma B., Perricaudet M. 1990; Construction of a defective adenovirus expressing the pseudorabies virus glycoprotein gp50 and its use as a five vaccine. Journal of General Virology 71:2425–2431
     [Google Scholar]
  12. Epstein M. A., Achong B. G. 1986 The Epstein-Barr Virus: Recent Advances. London: Heinemann Medical Books;
     [Google Scholar]
  13. Epstein M. A., Morgan A. J., Finerty S., Randle B. J., Kirkwood J. K. 1985; Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature, London 318:287–289
     [Google Scholar]
  14. Epstein M. A., Randle B. J., Finerty S., Kirkwood J. K. 1986; Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. Clinical and Experimental Immunology 63:485–490
     [Google Scholar]
  15. Graham F. L., Smiley J., Russell W. C., Nairn R. 1977; Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Journal of General Virology 36:59–72
     [Google Scholar]
  16. Grierson H., Purtilo D. T. 1987; Epstein-Barr virus infections in males with the X linked lymphoproliferative syndrome. Annals of Internal Medicine 106:538–545
     [Google Scholar]
  17. Henlé G., Henlé W. 1966; Immunofluorescence in cells derived from BL. Journal of Bacteriology 91:1248–1256
     [Google Scholar]
  18. Kasel J. A. 1980 Adenoviruses. In Viral, Rickettsial and Chlamydial Infections Edited by Lennette E., Schmidt N. New York: American Public Health Association;
     [Google Scholar]
  19. Khyatti M., Patel P. C, Stefanescu I., Menezes J. 1991; Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cytotoxicity. Journal of Virology 65:996–1001
     [Google Scholar]
  20. Lee M. S., Roos J. M., McGuigan L. C., Smith K. A., Cormier N., Cohen L. K., Roberts B. E., Payne L. G. 1992; Molecular attenuation of vaccinia virus: mutant generation and animal characterization. Journal of Virology 66:2617–2630
     [Google Scholar]
  21. Levrero M., Barbant V., Manteca S., Ballay A., Balsamo C., Avantaggiati M. L., Natoli G., Skellekens H., Tiollais P., Perricaudet M. 1991; Defective and nondefective adenovirus vector for expressing foreign genes in vitro and in vivo. Gene. 101:195–201
     [Google Scholar]
  22. Lowe S. R., Keller P. M., Keech B. J., Davison A. J., Whang Y., Morgan A. J., Kieff E., Ellis R. 1987; Varicella-zoster virus as a live vector for the expression of foreign genes. Proceedings of the National Academy of Sciences, U. S. A. 84:3896–3900
     [Google Scholar]
  23. Lubeck M. D., Davis A. R., Chengalva M., Natuk R. J., Morin J. E., Molnar-Kimber K., Masson B. B., Bhat B. M., Mizutani S., Hung P. P., Purcell R. H. 1989; Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis vaccine based on live recombinant adenovirus. Proceedings of the National Academy of Sciences, U. S. A. 86:6763–6767
     [Google Scholar]
  24. McDermott M. R., Graham F. L., Hanke T., Johnson D. C. 1989; Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B. Virology 169:244–247
     [Google Scholar]
  25. Morgan A. J. 1992; Epstein-Barr virus vaccines. Vaccine 10:563–572
     [Google Scholar]
  26. Morgan A. J., North J. R., Epstein M. A. 1983; Purification and properties of the gp340 component of Epstein-Barr virus membrane antigen in an immunogenic form. Journal of General Virology 64:455–460
     [Google Scholar]
  27. Morgan A. J., Epstein M. A., North J. R. 1984; Comparative immunogenicity studies on Epstein-Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits and cotton-top tamarins. Journal of Medical Virology 13:281–292
     [Google Scholar]
  28. Morgan A. J., Finerty S., Lovgren K., Scullion F. T., Morein B. 1988a; Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. Journal of General Virology 69:2093–2096
     [Google Scholar]
  29. Morgan A. J., Mackett M., Finerty S., Arrand J. R., Scullion F. T., Epstein M. A. 1988b; Recombinant vaccinia virus expressing glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. Journal of Medical Virology 25:189–195
     [Google Scholar]
  30. Morgan A. J., Allison A. C, Finerty S., Scullion F. T., Byars N. E., Epstein M. A. 1989; Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use. Journal of Medical Virology 29:74–78
     [Google Scholar]
  31. Müller N., Evans A., Harris N. L., Comstock G. W., Jellum E., Magnus K., Orentreich N., Polk B. F., Vogelman J. 1989; Hodgkin’s disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. New England Journal of Medicine 320:689–695
     [Google Scholar]
  32. Müller R. E., Muldoon R. L., Jackson G. G. 1969; Communicability of enteric live adenovirus type 4 vaccine in families. Journal of Infectious Diseases 119:60–66
     [Google Scholar]
  33. Murphy F. A. 1989; Vaccinia-vectored vaccines, risks and benefits. Research in Virology 140:463–491
     [Google Scholar]
  34. Pallesen G., Hamilton-Dutoit S. J., Rowe M., Young L. S. 1991; Expression of Epstein Barr virus latent gene products in tumour cells of Hodgkin’s disease. Lancet 337:320–322
     [Google Scholar]
  35. Parkin D. M., Stjemsward J., Muir C. S. 1984; Estimates for the worldwide frequency of twelve major cancers. Bulletin of the World Health Organization 62:163–182
     [Google Scholar]
  36. Prevec L., Schneider M., Rosenthal K. L., Belbeck L. W., Derbyshire J. B., Graham F. L. 1989; Use of human adenovirus-based vectors for antigen expression in animals. Journal of General Virology 70:429–434 erratum 2539
    [Google Scholar]
  37. Prevec L., Campbell J. B., Christie B. S., Belbeck L., Graham F. 1990; A recombinant human adenovirus vaccine against rabies. Journal of Infectious Diseases 61:27–30
     [Google Scholar]
  38. Raab-Traub N., Rajadurai P., Flynn K., Lanier A. P. 1991; Epstein-Barr virus infection in carcinoma of the salivary gland. Journal of Virology 65:7032–7036
     [Google Scholar]
  39. Ragot T., Tosoni-Pittoni E., Finerty S., Morgan A. J., Perricaudet M. 1990; Recombinant adenoviruses which express the EBV major membrane antigen gp340/220 induce persistent EBV-neutralizing antibodies in rabbits. In Epstein-Barr Virus and Human Disease pp. 231–236 Edited by Ablashi D. V., Huang A. T., Pagano J. S., Pearson G. R., Yang C. S. Clifton, New Jersey: Humana Press;
     [Google Scholar]
  40. Ragot T., Eloit M., Perricaudet M. 1991; Recombinant E1A-defective adenoviruses expressing pseudorabies and Epstein-Barr virus glycoproteins induce immunological response as live vaccines in rabbits and mice. In Human Gene Transfer pp. 249–260 Edited by Cohen-Haguenauer O., Boiron M. London: John Libbey & Co;
     [Google Scholar]
  41. Randle B. J., Epstein M. A. 1984; A highly sensitive enzyme-linked immunosorbent assay to quantitate antibodies to Epstein-Barr virus membrane antigen gp340. Journal of Virological Methods 9:201–208
     [Google Scholar]
  42. Rooney J. F., Wohlenberg C., Cremer K. J., Moss B., Notkins A. L. 1988; Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D, long-term protection and effect of revaccination. Journal of Virology 62:1530–1534
     [Google Scholar]
  43. Rosen I. 1960; A hemagglutination-inhibition technique for typing adenoviruses. American Journal of Hygiene 71:120–128
     [Google Scholar]
  44. Schwartz A. R., Togo Y., Hornick R. B. 1974; Clinical evaluation of live, oral types 1, 2 and 5 adenovirus vaccines. American Review of Respiratory Disease 109:233–238
     [Google Scholar]
  45. Shenk T., Williams J. 1984; Genetic analysis of adenovirus. Current Topics in Microbiology and Immunology 11:1–39
     [Google Scholar]
  46. Stanley E. D., Jackson G. G. 1969; Spread of enteric live adenovirus type 4 vaccine in married couples. Journal of Infectious Diseases 119:51–59
     [Google Scholar]
  47. Tacket C. O., Losonsky G., Lubeck M. D., Davis A. R., Mizutani S., Horwith G., Hung P. P., Edelman R., Levine M. M. 1992; Initial safety and immunogenicity studies of oral recombinant adenohepatitis B vaccine. Vaccine 10:673–676
     [Google Scholar]
  48. Tartaglia J., Perkus M. E., Taylor J., Norton E. K., Audonnet J.-C., Cox W. L, Davis S. W., van der Hoeven J., Meignier B., Riviere M., Languet B., Paoletti E. 1992; NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217–232
     [Google Scholar]
  49. Taylor J., Weinberg R., Tartaglia J., Richardson C., Alkhatib G., Briedis D., Appel M., Norton E., Paoletti E. 1992; Nonreplicating viral vectors as potential vaccines, recombinant canarypox vims expressing measles vims fusion (F) and hemagglutinin (HA) glycoproteins. Virology 187:321–328
     [Google Scholar]
  50. Thomas J. A., Crawford D. H. 1989; Epstein-Barr virus associated B-cell lymphomas in AIDS and after organ transplantation. Lancet i:1075–1076
     [Google Scholar]
  51. Top F. H. Jr, Grossman R. A., Bartelloni P. J., Segal H. E., Dudding B. A., Russell P. K. B., scher E. L. 1971a; Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. Journal of Infectious Diseases 124:148–154
     [Google Scholar]
  52. Top F. H. Jr, Büscher E. L., Bancroft W. H., Russell P. K. 1971b; Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. Journal of Infectious Diseases 124:155–160
     [Google Scholar]
  53. Wallace L. E., Wright J., Ulaeto D. O., Morgan A. J., Rickinson A. B. 1991; Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones. Journal of Virology 65:3821–3828
     [Google Scholar]
  54. Williamson J. D., Reith R. W., Jeffrey L. J., Arrand J. R., Mackett M. 1990; Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. Journal of General Virology 71:2761–2767
     [Google Scholar]
/content/journal/jgv/10.1099/0022-1317-74-3-501
Loading
Replication-defective recombinant adenovirus expressing the Epstein—Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin
J. Gen. Virol. 74, 501 (1993); https://doi.org/10.1099/0022-1317-74-3-501
/content/journal/jgv/10.1099/0022-1317-74-3-501
/content/journal/jgv/10.1099/0022-1317-74-3-501
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error